Lördag 20 December | 14:26:47 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-08-20 08:30 Kvartalsrapport 2026-Q2
2026-05-07 N/A Årsstämma
2026-05-07 08:30 Kvartalsrapport 2026-Q1
2026-02-20 08:30 Bokslutskommuniké 2025
2025-11-27 - Kvartalsrapport 2025-Q3
2025-10-10 - Extra Bolagsstämma 2025
2025-08-11 - Kvartalsrapport 2025-Q2
2025-05-08 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2025-05-07 - Årsstämma
2025-05-07 - Kvartalsrapport 2025-Q1
2025-02-20 - Bokslutskommuniké 2024
2024-10-31 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-05-08 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2024-05-07 - Årsstämma
2024-05-07 - Kvartalsrapport 2024-Q1
2024-02-22 - Bokslutskommuniké 2023
2023-10-31 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2023-05-25 - Årsstämma
2023-05-03 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-02 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-30 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2022-05-27 - Årsstämma
2022-05-06 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-24 - Extra Bolagsstämma 2021
2021-10-20 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2021-05-27 - Årsstämma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-02-17 - Bokslutskommuniké 2020
2020-11-03 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-28 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2020-05-27 - Årsstämma
2020-04-28 - Kvartalsrapport 2020-Q1
2020-02-17 - Bokslutskommuniké 2019
2019-10-31 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-06-04 - Årsstämma
2019-05-23 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2019-04-30 - Kvartalsrapport 2019-Q1
2019-02-15 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriMedicinteknik
Lumito är ett svenskt bolag som utvecklar och marknadsför system för vävnads- och biomarköranalys inom digital patologi, byggda på uppkonverterande nanopartikelteknik. Bolaget riktar sig till vårdinrättningar, forskning och läkemedelssektorn. Bolaget bildades 2010 som en spinoff från en forskargrupp vid Lunds universitets avdelning för atomfysik och lasercentrum. Lumito har sitt huvudkontor i Lund.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-12-19 15:00:00

Lumito AB’s (publ) (“Lumito” or “the Company”) Board of Directors proposes that an extraordinary general meeting resolves on a reverse share split, whereby five hundred (500) existing shares are consolidated into one (1) new share. If the extraordinary general meeting resolves in accordance with the proposal, the total number of shares in the Company will decrease from the current 1,720,448,151 shares to approximately 3.4 million shares. The Board further proposes that the extraordinary general meeting resolve on a reduction in the restricted capital (the share capital). The proposals will be presented in detail in a separate notice convening the extraordinary general meeting.

Reversed share split
The rationale behind the Board’s proposal, which is believed to be in the best interest of the Company and its shareholders, is that the Company currently has a very high number of outstanding shares combined with a relatively low market price per share, creating high volatility. The Board of Directors believes that a reverse share split would result in a more appropriate and reasonable trading price for the Company’s shares, and that the share price following the reverse share split will be more easily understood, as it will be expressed in Swedish kronor and öre rather than in fractions of an öre.

Lumito wishes to emphasise that a reverse share split does not, in principle, affect shareholders’ ownership proportions. Shareholdings will instead be represented by a smaller number of shares with a correspondingly higher nominal value. Consequently, the Company’s market capitalisation is also, in principle, unaffected by the reverse share split.

Should the extraordinary general meeting approve the reverse share split, the outstanding warrants of series TO7, which were issued in connection with the recently completed rights issue of units, will be subject to recalculation. Such recalculation will be carried out in accordance with the terms and conditions adopted at the time of issuance of the warrants. Further information regarding this recalculation will be communicated through a separate press release.

Share capital reduction
At the planned extraordinary general meeting, the Board of Directors also intends to propose a reduction of the Company’s restricted capital (the share capital), which has increased to a relatively high level following the most recent capital raising. This does not affect the total equity but is rather a reclassification of the restricted capital to unrestricted equity.

Notice for extraordinary general meeting
A notice convening the extraordinary general meeting to resolve on the above matters will be published through a separate press release in the near future.